Atrium Therapeutics Inc RNA
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-02-27 |
| Shares Out. | 17,110,000 |
| Phone | 13026587581 |
| Employees | 391 |
| Website | aviditybiosciences.com ↗ |
| Revenue | $19.6M |
| Gross Profit | $19.6M |
| Net Income | -$16.6M |
| Total Assets | $292.4M |
| Total Liabilities | $58.3M |
| Equity | $234.1M |
About Atrium Therapeutics Inc
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Atrium Therapeutics Inc is a publicly traded company under the ticker symbol RNA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)